Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Medical Teacher
|
May 14, 2020
Mixed reality as a time-efficient alternative to cadaveric dissection
Jeremy S Ruthberg, Galen Tingle, Lisa Tan, et al.
British Journal of Clinical Pharmacology
|
December 7, 2018
Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler
Jason Perry, Brian Trautman, Joe Takher-Smith, et al.
American Journal of Hematology
|
January 19, 2021
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro, Federico Grossi, Ilene Ceil Weitz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 2006
Interstitial radiation therapy for early-stage nasal vestibule cancer: a continuing quest for optimal tumor control and cosmesis
Peter C Levendag, Wideke M Nijdam, Sanne E van Moolenburgh, et al.
British Journal of Clinical Pharmacology
|
November 8, 2019
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics
David L Hava, Lisa Tan, Patrick Johnson, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
Beatrice Gini, Philippe Gui, Wei Wu, et al.
Advances in Therapy
|
April 4, 2024
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Christopher J Patriquin, Andrija Bogdanovic, Morag Griffin, et al.
Annals of Hematology
|
July 22, 2022
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
Raymond S M Wong, Humphrey W H Pullon, Ismail Amine, et al.
The New England Journal of Medicine
|
March 17, 2021
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen, Jeff Szer, Ilene Weitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study
Collin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Medical Teacher
|
May 14, 2020
Mixed reality as a time-efficient alternative to cadaveric dissection
Jeremy S Ruthberg, Galen Tingle, Lisa Tan, et al.
British Journal of Clinical Pharmacology
|
December 7, 2018
Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler
Jason Perry, Brian Trautman, Joe Takher-Smith, et al.
American Journal of Hematology
|
January 19, 2021
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro, Federico Grossi, Ilene Ceil Weitz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 2006
Interstitial radiation therapy for early-stage nasal vestibule cancer: a continuing quest for optimal tumor control and cosmesis
Peter C Levendag, Wideke M Nijdam, Sanne E van Moolenburgh, et al.
British Journal of Clinical Pharmacology
|
November 8, 2019
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics
David L Hava, Lisa Tan, Patrick Johnson, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
Beatrice Gini, Philippe Gui, Wei Wu, et al.
Advances in Therapy
|
April 4, 2024
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Christopher J Patriquin, Andrija Bogdanovic, Morag Griffin, et al.
Annals of Hematology
|
July 22, 2022
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
Raymond S M Wong, Humphrey W H Pullon, Ismail Amine, et al.
The New England Journal of Medicine
|
March 17, 2021
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen, Jeff Szer, Ilene Weitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study
Collin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.
Page
of 3